Serpin Pharma Completed a phase I trial in 24 individuals and has filed with the FDA for treatment of patients with Alpha-1 antitrypsin (AAT) deficiency

Serpin Pharma Completed a phase I trial in 24 individuals and has filed with the FDA for treatment of patients with Alpha-1 antitrypsin (AAT) deficiency
<span><b id="docs-internal-guid-bf69fe8c-7fff-dc30-e1ff-fb3ccb48e6cf">Serpin Pharma (<a href="http://www.serpinpharma.com/">http://www.serpinpharma.com/</a>) announced the successful completion of its Phase I clinical study in January 2019.&nbsp; The double blinded, placebo control trial was conducted in Virginia Commonwealth University (VCU) Medical Center under the leadership of a world renown cardiologist, Dr. Antonio Abbate.</b></span>

 

Manassas, VA • June 17, 2019

Serpin Pharma (http://www.serpinpharma.com/) announced the successful completion of its Phase I clinical study in January 2019.  The double blinded, placebo control trial was conducted in Virginia Commonwealth University (VCU) Medical Center under the leadership of a world renown cardiologist, Dr. Antonio Abbate. Following the completion of Phase I, Serpin Pharma is poised to launch Phase II clinical trials in atopic dermatitis, acute lung injury and a rare indication (AAT deficiency). The studies are planned to commence later this year in collaboration with major hospitals and academic institutions.

Serpin Pharma is developing a first in class, short peptide drug (SP16) that is derived from an existing drug, Alpha 1 anti Trypsin Deficiency (AATD).  AATD is a rare hereditary condition that leads to decreased circulating alpha-1 antitrypsin (AAT) levels, significantly increasing the risk of serious lung and/or liver disease in children and adults, in which some aspects remain unresolved.

Alpha-1 Antitrypsin (AAT) that is currently marketed for replacement therapy. 

SP16 is positioned as a Bio-Superior to the plasma-purified, marketed AAT to treat inflammatory and autoimmune diseases, exhibiting superior potency over AAT. SP16 contains precise anti-inflammatory properties versus AAT which exhibits both anti-inflammatory and pro-inflammatory properties. SP16 acts as an LRP1 agonist, a critical signaling receptor that drives inflammatory resolution and healing. 

Moreover, additional advantages of SP16 to the patients stem from the fact that SP16 will be given as a subcutaneous, self-administered injection (in comparison with the 30-60 minutes intravenous infusion in a clinic) and its cost to the patient would be a small fraction of the existing AAT drug.

Serpin Pharma was awarded a second Virginia Catalyst grant to further elucidate intracellular, signal transduction pathways underpinning the potency and versatility of SP16 once engaged with its cognate receptor.

 

Serpin Pharma operates at Innovation Park within Prince William County Science Accelerator and is led by serial entrepreneurs Dr. Cohava Gelber and Guy Yachin.

Source: serpinpharma.com